CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从抑制因子到增强因子：IL-10 在实体瘤 CAR-T 细胞治疗中的另类作用
英文原题：From suppressor to enhancer: IL-10's alternative role in CAR-T cell therapies against solid tumors.
查看英文原题
From suppressor to enhancer: IL-10's alternative role in CAR-T cell therapies against solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
为了提升CAR-T 细胞的效应功能，Zhao等人1报道IL-10可对CAR-T 细胞进行代谢重编程，从而增强其对抗实体瘤的有效性，并挑战了IL-10仅被视为免疫抑制因子的传统认知。这一简单却充满前景的策略有助于建立持久的免疫记忆，亟待在临床试验中得到验证。
展开英文摘要原文
Aiming to improve the effector function of CAR-T cells, Zhao et al. 1 report that IL-10 metabolically reprograms CAR-T cells, and this promotes their effectiveness against solid tumors and challenges IL-10's perceived role as merely immunosuppressive. This simple but promising strategy fosters durable immune memory and eagerly awaits validation in clinical trials.
论文信息
- 作者
- Huang Y、Wang H
- 第一作者单位
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China; Lingang Laboratory, Shanghai 200031, China.China
- 通讯作者单位
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China; State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China; Shanghai Clinical Research and Trial Center, Shanghai, China. Electronic address: wanghp@shanghaitech.edu.cn.China
- 期刊
- Cell stem cell2024 Mar 7
- 原文标识
- PubMed 38458175 · DOI 10.1016/j.stem.2024.02.003